Maniradhan · Endocrine, metabolic & immune disorders drug targets 2023 · narrative review · n=?

Bisphenol A-Induced Endocrine Dysfunction and its Associated Metabolic Disorders.

Cited 52 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative review synthesizing mechanistic and molecular pathways without systematic methodology.

PubMed 36173044 · doi:10.2174/1871530322666220928144043 · record verified 2026-08-28

What was done

This narrative review summarizes literature regarding the cellular and molecular mechanisms of bisphenol A (BPA) exposure and its associated endocrine dysfunctions and metabolic disorders, including obesity, fatty liver diseases, insulin resistance, and polycystic ovarian syndrome.

What was found

The abstract reports no numerical findings, effect estimates, or sample metrics. It qualitatively describes mechanisms whereby BPA acts as an agonist or antagonist via estrogen and G-protein coupled receptors, activates pathways influencing apoptosis and inflammation, stimulates adipogenesis and lipid accumulation, elevates oxidative mediators, reduces antioxidant enzymes, and causes mitochondrial dysfunction.

Why it matters

It provides an overview of putative molecular and cellular pathways through which environmental exposure to BPA can contribute to metabolic syndrome and related endocrine disorders.

Limits

The abstract describes a narrative review without systematic search protocols, quality appraisal, or study selection criteria. It provides no quantitative data, human clinical outcome measurements, or exposure threshold details, relying primarily on mechanistic reasoning.

Cited by